A detailed history of Woodline Partners LP transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 865,794 shares of ARWR stock, worth $18.5 Million. This represents 0.15% of its overall portfolio holdings.

Number of Shares
865,794
Previous 821,518 5.39%
Holding current value
$18.5 Million
Previous $21.4 Million 21.5%
% of portfolio
0.15%
Previous 0.21%

Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$19.36 - $29.54 $857,183 - $1.31 Million
44,276 Added 5.39%
865,794 $16.8 Million
Q2 2024

Aug 14, 2024

BUY
$21.87 - $28.24 $5.82 Million - $7.51 Million
265,890 Added 47.85%
821,518 $21.4 Million
Q1 2024

May 15, 2024

SELL
$27.21 - $39.48 $10.1 Million - $14.7 Million
-371,559 Reduced 40.07%
555,628 $15.9 Million
Q4 2023

Feb 14, 2024

BUY
$21.2 - $31.03 $9.72 Million - $14.2 Million
458,690 Added 97.91%
927,187 $28.4 Million
Q3 2023

Nov 14, 2023

BUY
$26.2 - $36.08 $9.76 Million - $13.4 Million
372,530 Added 388.19%
468,497 $12.6 Million
Q2 2023

Aug 14, 2023

SELL
$25.16 - $41.38 $12.5 Million - $20.5 Million
-496,271 Reduced 83.8%
95,967 $3.42 Million
Q1 2023

May 15, 2023

BUY
$23.68 - $38.51 $14 Million - $22.8 Million
592,238 New
592,238 $15 Million
Q4 2020

Feb 16, 2021

SELL
$43.82 - $85.37 $3.83 Million - $7.46 Million
-87,365 Closed
0 $0
Q3 2020

Nov 16, 2020

BUY
$33.21 - $51.27 $2.9 Million - $4.48 Million
87,365 New
87,365 $3.76 Million

Others Institutions Holding ARWR

About ARROWHEAD PHARMACEUTICALS, INC.


  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $2.27B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.